Pharmaceuticals

Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient - The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval - The FDA on Monday approved the first-ever GLP-1 pill from the Danish pharmaceutical giant.
Nine of the largest pharma companies ink deals with Trump to lower drug prices - President Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.
UnitedHealth Group commits to improvements after independent audit, patient backlash - The company said it has adopted 23 ongoing "action plans" to track and implement recommended improvements, all of which will be completed by the end of March.
This is how exposed European Big Pharma is to the U.S. - U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
Trump signs executive order reclassifying cannabis, opening door to broader weed access - President Donald Trump signed an executive order Thursday reclassifying marijuana as a Schedule III substance with looser restrictions.
Medical supply firm Medline jumps more than 25% in debut after biggest IPO of 2025 - Medline priced at $29 per share on Tuesday, raising $6.26 billion to cap off a strong year for new listings and bolster optimism about 2026.
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.
RFK Jr.'s vaccine panel to vote on changing hepatitis B shot recommendation for babies - The current recommendation for babies to receive a hepatitis B shot within 24 hours of birth is credited with driving down infections in kids by 99%.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.